Analyst Price Targets — CAMP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 10, 2026 8:19 am | Keay Nakae | Chardan Capital | $6.50 | $4.01 | TheFly | Camp4 Therapeutics initiated with a Buy at Chardan |
| October 2, 2025 10:35 am | — | Cantor Fitzgerald | $7.00 | $2.95 | TheFly | Camp4 Therapeutics initiated with an Overweight at Cantor Fitzgerald |
| November 5, 2024 11:10 am | Mani Foroohar | Leerink Partners | $17.00 | $9.60 | StreetInsider | Leerink Partners Starts CAMP4 Therapeutics Corp (CAMP) at Outperform |
| November 5, 2024 8:42 am | Edward Tenthoff | Piper Sandler | $18.00 | $9.60 | StreetInsider | Piper Sandler Starts CAMP4 Therapeutics Corp (CAMP) at Overweight |
| August 16, 2022 8:47 am | Anthony Stoss | Craig-Hallum | $10.00 | $5.80 | TheFly | Craig-Hallum upgrades CalAmp to Buy, raises price target to $10 |
| June 24, 2022 2:37 pm | Jerry Revich | Goldman Sachs | $5.00 | $4.93 | TheFly | Goldman Sachs cuts CalAmp EBITDA estimates on lower margin forecasts |
Latest News for CAMP
CAMBRIDGE, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on July 15, 2026 (the “Grant…
CAMBRIDGE, Mass. , July 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on July 15, 2026 (the "Grant…
AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.
CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the “Grant…
CAMBRIDGE, Mass. , June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the "Grant…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CAMP.
U.S. House Trading
No House trades found for CAMP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.